- Open
- 1.25
- High
- 1.30
- Low
- 1.07
- Close
- 1.13
- Change
- -0.15 (-12.00%)
- Volume
- 13,647,404
⌘K
| 4 Jun 2026 | 18:02:26 | Holding(s) in Company |
| 3 Jun 2026 | 11:03:10 | Holding(s) in Company |
| 22 May 2026 | 07:00:06 | Notice of Results |
| 8 May 2026 | 16:06:41 | Holding(s) in Company |
| 7 May 2026 | 07:00:08 | Grant of Share Options & PDMR Dealings |
| 10 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 8 Jul 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 10 Jul 2023 | Annual Report and Accounts (to 2022-12-31) |
GENinCode is a company that focuses on assessing the risk of cardiovascular disease, which is the primary cause of death and disability globally. Their products utilize a combination of genetic and clinical data to provide healthcare professionals with advanced clinical information for patient risk assessment.
| 4 Jun 2026 | 18:02:26 | Holding(s) in Company |
| 3 Jun 2026 | 11:03:10 | Holding(s) in Company |
| 22 May 2026 | 07:00:06 | Notice of Results |
| 8 May 2026 | 16:06:41 | Holding(s) in Company |
| 7 May 2026 | 07:00:08 | Grant of Share Options & PDMR Dealings |
| 10 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 8 Jul 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 10 Jul 2023 | Annual Report and Accounts (to 2022-12-31) |
GENinCode is a company that focuses on assessing the risk of cardiovascular disease, which is the primary cause of death and disability globally. Their products utilize a combination of genetic and clinical data to provide healthcare professionals with advanced clinical information for patient risk assessment.
